news, journals and articles from all over the world.
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
Read moreErlanger Health System and Vanderbilt University Medical Center, on behalf of Vanderbilt-Ingram Cancer Center (VICC), have entered into an agreement to design a long-term collaboration in cancer care, including VICC hematology-oncology services at Erlanger’s two clinic and infusion locations.
Read moreMemorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.
Read more
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
Read more
“Thanks to Andre Goy’s leadership, John Theurer Cancer Center has flourished to become one of the nation’s leading cancer care and research centers, and that expertise now extends throughout our entire network,” noted Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. “With Dr. Goy at the helm as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service, patients and physicians throughout the state will benefit from his acumen and vision.”
Read more
Yale Cancer Center scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair. These mutation-driven “oncometabolites” may make cells more prone to developing cancer—but also more vulnerable to new cancer treatment strategies.
Read more
Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.
Read more
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
Read more
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Read moreAt-home genetic-testing kits for breast and ovarian cancer risk are just as effective, and in some cases even more so, than the typical protocol for genetic testing, which requires repeated office visits and counseling, according to a study led by UW Medicine researchers.
Read moreUpon exposure to human skin, ultraviolet light from the sun almost instantly generates two types of “lesions” that damage DNA. Scientists at UW Medicine in Seattle determined which of these lesions is responsible for activating a process that may increase cancerous mutations in cells.
Read more
New study reveals impact of COVID-19 pandemic on cancer clinical trials, published in Nature Reviews Drug Discovery
Read more